Stock Information
Inhibrx Biosciences Inc (INBX)
Ticker Symbol: INBX
Exchange: NASDAQ
Sector: Biotechnology
Market Cap: $1,390.88 mil
Piotroski score: 2
PE Ratio: N/A
EPS (TTM): -6.2439
Revenue (TTM): $0.08 M
Dividend Yield: N/A%
ROE: -255.98%
Latest News
-
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
Mon, Jun 15, 2026 1:15 PM
-
Inhibrx Biosciences Says FDA Accepts BLA Seeking Approval Of Ozekibart In Patients With Conventional Chondrosarcoma; PDUFA Goal Date Set For April 14, 2027
Mon, Jun 15, 2026 9:19 AM
Key Financials
Financial data not available
